Article

Pfizer Taps Harvard's Ole Isacson as CSO of Neuroscience Research Unit

September 12, 2016

Pfizer has announced that Dr. Ole Isacson will become its Chief Scientific Officer of the Neuroscience Research Unit and Senior Vice President, effective September 16. 

Dr. Isacson is a Professor of Neurology at Harvard Medical School, and will continue to serve in an educational role. He is also a founding director of the Neuroregeneration Institute at McLean Hospital. 

Dr. Isacson will report directly to Mikael Dolsten, President of Worldwide Research and Development.

Newsletter

Lead with insight with the Pharmaceutical Executive newsletter, featuring strategic analysis, leadership trends, and market intelligence for biopharma decision-makers.

Subscribe Now!
Related Videos
Gen Li
Gen Li
Ted Sweetser
Ted Sweetser
Ted Sweetser
Related Content
Peter Tummino
August 5th 2025

Computational Chemistry in Drug Discovery: Q&A with Dr. Peter Tummino

Mike Hollan
Computational chemistry combined with AI technologies has become a powerful tool for assessing small molecule properties, high-resolution protein structures, and molecular mechanism of action, as well as optimizing target selection and small molecule design.
Revolutionizing Patient Adherence: Leveraging AI for Personalized Engagement
August 5th 2025

Revolutionizing Patient Adherence: Leveraging AI for Personalized Engagement

Miranda Schmalfuhs
Bill Grambley, CEO of AllazoHealth, delves into the potential of AI to revolutionize patient engagement and adherence.
Gaugarin Oliver
August 5th 2025

Navigating Uncertainty with AI: Building Trust in the Way Forward

Gaugarin Oliver
Despite surging GenAI adoption in pharma and the FDA’s recent embrace of the technology, a trust gap remains with GenAI implementations. The story describes four essentials that improve trust in GenAI so that pharma and biotech teams can better navigate the present time of uncertainty.
Zifo Survey Shows Biopharma Racing Toward AI Despite Data Management Challenges
August 5th 2025

Zifo Survey Shows Biopharma Racing Toward AI Despite Data Management Challenges

Don Tracy, Associate Editor
A global survey of scientists and informaticians reveals growing AI investment across the biopharma value chain, but highlights gaps in data integration, standardization, and infrastructure that threaten to stall progress.
Stock.adobe.com
August 5th 2025

Can AI Accelerate Clinical Review at FDA?

PharmExec Staff
With reports that FDA’s AI Elsa is “confidently hallucinating” studies that don’t exist, the use of AI to streamline drug review and speed up approval is not here yet.
Snyder and Capan
August 5th 2025

Accelerating AI: Q&A with Faruk Capan and Scott Snyder

Pharmaceutical Executive
The EVERSANA team discusses its new technology center that has a goal of pharmatizing AI.